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Abstract
Background: Herpes zoster is common and has serious consequences, notably post-herpetic neuralgia (PHN). Vaccine
efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effectiveness has not been studied in
unselected general populations unrestricted by region, full health insurance coverage, or immune status. Our objective was
to assess zoster vaccine effectiveness (VE) against incident zoster and PHN in a general population-based setting.
Methods and Findings: A cohort study of 766,330 fully eligible individuals aged $65 years was undertaken in a 5% random
sample of Medicare who received and did not receive zoster vaccination between 1st January 2007 and 31st December
2009. Incidence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated individuals.
Analyses were adjusted for age, gender, race, low income, immunosuppression, and important comorbidities associated
with zoster, and then stratified by immunosuppression status. Adjusted hazard ratios were estimated using time-updated
Cox proportional hazards models. Vaccine uptake was low (3.9%) particularly among black people (0.3%) and those with
evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident zoster; the overall zoster incidence rate
was 10.0 (9.8–10.2) per 1,000 person-years in the unvaccinated group and 5.4 (95% CI 4.6–6.4) per 1,000 person-years in
vaccinees, giving an adjusted VE against incident zoster of 0.48 (95% CI 0.39–0.56). In immunosuppressed individuals, VE
against zoster was 0.37 (95% CI 0.06–0.58). VE against PHN was 0.59 (95% CI 0.21–0.79).
Conclusions: Vaccine uptake was low with variation in specific patient groups. In a general population cohort of older
individuals, zoster vaccination was associated with reduction in incident zoster, including among those with
immunosuppression. Importantly, this study demonstrates that zoster vaccination is associated with a reduction in PHN.
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Introduction
Herpes zoster is a significant public health problem affecting 1
million individuals in the US per year and associated with
important sequelae [1,2]. Herpes zoster occurs following reacti-
vation of latent varicella zoster virus (VZV) infection and presents
with a painful vesicular rash, which frequently in older individuals
leads to prolonged pain, post-herpetic neuralgia (PHN), with a
major impact on quality of life [2]. Vaccine efficacy has been
shown in trials [3,4]; in a selected insured population [5]; and
among people with any of five specific immune-mediated diseases
[6] but not among an unselected population in a clinical setting.
Zhang et al. demonstrated that despite Advisory Committee for
Immunization Practices (ACIP) recommendations, individuals
with immunosuppression received the live herpes zoster vaccine
in clinical practice [7]. The lack of adherence to ACIP
recommendations on vaccination is not entirely surprising given
that individuals with immunosuppression are not only at increased
risk of incident herpes zoster but also at significantly increased risk
of herpes zoster complications, in particular prolonged, severe
PHN [8,9]. Previous research has suggested that the varicella
vaccine may be efficacious and safe in people with immunosup-
pressive disorders [10–12]. Similar evidence about vaccine
effectiveness (VE) is lacking in relation to the zoster vaccine in
individuals with serious immune suppression, beyond effectiveness
among those with the selected immune-mediated disorders
examined to date.
Important outstanding research questions with great relevance
to policy include VE in unselected population-based elderly US
populations; this includes effectiveness against PHN, which has not
been assessed in routine practice. The report by Zhang et al. also
highlights the additional importance of studying further VE in
those with immunosuppression [6]. This is the first study to the
best of our knowledge to assess the effectiveness of herpes zoster
vaccine against both incident herpes zoster and PHN in an
unselected older population including those with immunosuppres-
sion.
Methods
Ethics
Ethics approval was obtained from Centers for Medicare &
Medicaid Services (CMS) (data use agreement 21520) and the
Ethics committee of the London School of Hygiene and Tropical
Medicine. Any data cell containing fewer than 11 beneficiaries
have not been shown as per the CMS Data Use Agreement.
Data Source
Medicare is a US administrative claims program mainly for
individuals aged .65 y covering 15% of the US population.
There are 44 million beneficiaries, of which more than half the
individuals are aged 65–75 y.[13] This study was based on the 5%
random Medicare Standard Analytic Files (SAF) including
Denominator, Inpatient hospital discharge records (MedPAR),
Physician/Supplier (Carrier) and Outpatient files from January 1st
2007 to December 31st 2009 obtained from the CMS.
Study Population
Study participants were aged 65 y or greater with at least 12 mo
continuous enrolment in Medicare parts A (which covers inpatient
care) and B (physician services and facility charges) and at least
6 mo continuous enrolment in part D (drug benefits) of Medicare.
The start of follow-up was the first date an individual fulfilled all
the eligibility criteria with an additional 12-mo baseline pre-study
observation period added to ensure observation of incident rather
than prevalent zoster. End of follow-up was defined as the earliest
of end of eligibility, date of death, development of herpes zoster, or
the end of the study period. Individuals enrolled in health
maintenance organizations or Medicare Advantage plans were
excluded from the study as their records are not processed by
CMS, hence information on clinical events is not available.
Individuals with episodes of herpes zoster in the first year pre-study
observation period were excluded from analysis to exclude
prevalent cases. Additionally, individuals who received the herpes
zoster vaccine during the baseline pre-study observation period
were excluded from analysis (Figure 1).
Exposure
Herpes zoster vaccine was identified based on the presence of
Current Procedural Terminology (CPT) code 90736. Additionally,
specific National Drug Codes (NDCs) for herpes zoster vaccine
were identified. A definite administration date was considered
present if a CPT code 90741 or Healthcare Common Procedural
Coding system (HCPCS) code G0377 was present within 7 d of
vaccine purchase; otherwise the date of recording of the NDC
code for herpes zoster vaccine was considered to be the
administration date.
Outcomes
Incident herpes zoster cases were identified as those with both
the presence of a specific International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic
code for herpes zoster, excluding those with specific ICD-9-CM
codes for PHN, and the use of antivirals, including acyclovir,
famciclovir, or valacyclovir, within 7 d either before or after the
diagnostic code for herpes zoster [6]. Cases were identified from
outpatient, inpatient, or health care provider (carrier) files. The
approach of using both the presence of diagnostic codes and
receipt of antivirals was proposed by Zhang et al. to increase the
positive predictive value of a herpes zoster diagnosis in an
administrative data source [6]. Incident herpes zoster was defined
as an episode of herpes zoster without any evidence of herpes
zoster or PHN for at least 1 y previously. A sensitivity analysis was
undertaken defining incident herpes zoster as the presence of an
ICD-9 code for herpes zoster irrespective of receipt of antiviral
therapy. PHN was identified using a modification of the method
proposed by Klompas et al. for administrative sources [14]. On the
basis of this method, PHN was identified as those with a first
episode of zoster with a further zoster diagnostic code after 90 d
with a relevant prescription for analgesia, anticonvulsant, or
antidepressant therapy on the same day as the recorded
consultation. The presence of codes for non-specific neuralgia or
for neurological complications of zoster after 90 d was also
consistent with PHN. The PHN analysis was repeated after 30 d
using the same diagnostic criteria.
Covariates
Current age was determined using date of birth identified from
the Medicare beneficiary file; age was categorized into 5-y age
bands as a time-varying covariate. Age at the start of the study was
also modelled as a continuous variable in a sensitivity analysis.
Race was identified from the Medicare SAF Denominator files,
derived from the Social Security Administration’s master benefi-
ciary record (designated via self-report) and categorized into white,
black, and other (not including those with missing data on race). It
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is critical to study race in any study of zoster epidemiology as
incidence rates in individuals with black skin are significantly
lower than in white individuals [15]. ‘‘State buy -in’’ at any point
during follow-up was assessed as a marker for low income. ‘‘State
buy-in’’ reflects that the state pays Medicare premiums for an
individual who is eligible due to low income. It can be assumed
that people with state buy-in have resources that are less than
twice that of the Supplemental Security Income threshold; hence
‘‘state buy-in’’ can be used a proxy for low income. We also
determined the proportions of individuals receiving herpes zoster
vaccination and developing incident herpes zoster by state and
used these data to define quintiles of states defined by each of
these two variables.
Immunosuppression status was identified as a time-varying
covariate. Once individuals developed leukaemia, lymphoma, or
HIV, as determined by the presence of two diagnostic ICD-9-CM
codes on different days within outpatient, inpatient, or provider
files, they were defined as being immunosuppressed from that
Table 1. Person-years by vaccination status and characteristics.
Characteristic Person-Years (n)a
Percent Vaccinated 28,291
Person-Years (n)
Percent Unvaccinated 1,291,832
Person-Years (n)
Age (y)b
65–69 273,312 (202,703) 2.5 (8,783) 97.5 (193,920)
70–74 302,422 (160,833) 2.6 (8,039) 97.4 (152,794)
75–79 262,110 (142,496) 2.4 (6,154) 97.6 (136,342)
$80 482,278 (260,255) 1.5 (6,903) 98.5 (253,352)
Gender
Male 420,652 (247,941) 2.0 (9,148) 98.0 (238,793)
Female 899,469 (518,391) 2.2 (20,775) 97.8 (497,616)
Racec
Black 111,633 (66,506) 0.3 (390) 99.7 (66,119)
White 1,119,377 (646,805) 2.4 (28,016) 97.6 (618,789)
Other 87,562 (52,046) 1.6 (1,484) 98.4 (50,562)
Low income
No 990,649 (570,182) 2.6 (27,523) 97.4 (542,659)
Yes 329,472 (196,150) 0.6 (2,400) 99.4 (193,750)
COPD
No 960,243 (553,697) 2.4 (24,696) 97.6 (529,001)
Yes 359,878 (212,635) 1.4 (5,277) 98.6 (207,408)
IBD
No 1,298,483 (753,863) 2.1 (29,376) 97.9 (724,489)
Yes 21,638 (12,467) 2.5 (547) 97.5 (11,920)
Kidney disease
No 1,013,681 (582,568) 2.3 (25,370) 97.7 (557,198)
Yes 306,440 (183,764) 1.4 (4,553) 98.6 (179,211)
Diabetes mellitus
No 802,500 (466,316) 2.5 (21,111) 97.5 (445,205)
Yes 517,621 (300,016) 1.6 (8,812) 98.4 (291,204)
RA
No 1,249,788 (726,516) 2.2 (28,727) 97.8 (697,789)
Yes 70,333 (39,816) 1.6 (1,196) 98.4 (38,620)
SLE
No 1,311,411 (761,406) 2.1 (29,745) 97.9 (731,661)
Yes 8,710 (4,926) 2.0 (178) 98.0 (4,748)
Immune suppressiond
No 1,233,333 (625,409) 2.1 (24,392) 97.9 (601,017)
Yes 86,788 (140,923) 2.3 (5,531) 97.7 (135,392)
aIndividuals could contribute person-time to more than one category.
bFor determination of numbers, age at vaccination used if vaccinated; otherwise baseline age.
cMissing race information for 975 people (0.1%).
dAt any stage during the study.
IBD, inflammatory bowel disease; RA, rheumatoid arthritis.
doi:10.1371/journal.pmed.1001420.t001
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point forward. These specific disorders were selected as these are
specific ACIP contraindications for the zoster vaccine [7].
Immunosuppressive medications were identified from the part
D drug files and an individual was defined as being immunosup-
pressed for 6 mo following the prescription of any immunosup-
pressive medication. If a patient received a further script during
that period, they remained immunosuppressed. Other comorbid-
ities including immune-mediated disorders or others previously
identified as being associated with increased risks of zoster such as
chronic obstructive pulmonary disease (COPD), diabetes, and
systemic lupus erythematosis (SLE) were identified from medical
records by the presence of two ICD-9-CM codes on different days
in the outpatient or carrier (provider) files or one or more codes
from inpatient records. Individuals with autoimmune disorders
such as SLE were considered immunocompetent unless they
received immunosuppressive therapy; these disorders are not
ACIP contraindications to vaccination.
Statistical Analysis
Characteristics associated with receipt of the herpes zoster
vaccine were explored by examining proportions of person-years
of follow-up contributed by demographic and clinical attributes.
Incidence rates for herpes zoster and PHN overall and by
population characteristics were determined by identifying the
number of events divided by person-years of follow-up. Cox
regression was used to derive hazard ratios for herpes zoster and
PHN in the vaccinated compared with the unvaccinated,
adjusting for relevant confounders identified from the previous
literature [3,15], including age, gender, race, low income,
immunosuppression, and comorbidities associated with herpes
zoster, with age and immunosuppression being included in the
analysis as time-varying covariates. Other comorbidities including
COPD were treated as binary variables. State quintiles of
vaccination and zoster incidence were added to the model to
determine if they were confounders. Checks for collinearity were
undertaken by assessing variance inflation factors for independent
variables. Interaction terms were explored for associations
between vaccination and age group and gender. VE was
calculated as (1 – the adjusted hazard ratio). Stratified analysis
of VE by immune status was adjusted for demographic
characteristics with a sensitivity analysis adjusting for other
comorbidities. A further sensitivity analysis was undertaken
assessing VE against PHN using logistic regression amongst
those with zoster with at least 6 mo of follow-up following zoster.
All analyses were undertaken using STATA (version 11.0).
Results
Vaccination Rates
Of the 766,330 eligible participants, 29,785 (3.9% of people;
2.1% of person-time) had herpes zoster vaccination during the
study period. Vaccination rates were lower in the oldest age group
(1.5% in those aged 80 y or greater), in black individuals (0.3%
compared to 2.4% in white individuals), and lower in those with
evidence of low income (Table 1)—0.6% in those with evidence of
low income were vaccinated as compared to 2.6% in individuals
with no evidence of low income. 140,925 individuals were
immunosuppressed at some point during follow-up and 4,469 of
these individuals were immunosuppressed at the time of herpes
zoster vaccination.
Herpes zoster Incidence Rates
Incidence rates for herpes zoster using the antiviral definition
were higher in older age groups, in women, in those with any
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immunosuppression (adjusted hazard ratio 1.80 [95% CI 1.70–
1.90]) and in those with specified immune-mediated disorders,
including inflammatory bowel disease and SLE, and other
disorders such as chronic kidney disease and COPD (Table 2).
Lower incidence rates were seen in people who reported being
black (adjusted hazard ratio 0.51 ([95% CI 0.47–0.56]) and those
with any evidence of low income (adjusted hazard ratio 0.86 [95%
CI 0.82–0.90]).
Herpes zoster Vaccine Effectiveness
Overall, 154 vaccinees experienced incident herpes zoster
episodes (defined using the specific antiviral definition) during
28,291 person-years of follow-up compared to 12,958 events in
1,291,829 person-years of follow-up in those not vaccinated, giving
an incidence rate of herpes zoster in vaccinees of 5.4 (95% CI 4.6–
6.4) per 1,000 person-years compared to 10.0 (95% CI 9.8–10.2)
per 1,000 person-years in those not vaccinated. All variance
inflation factors were less than 1.2, suggesting collinearity was not
a major issue, and no significant interactions were detected. The
overall vaccine effectiveness (VE) for herpes zoster in vaccinees
adjusted for age, gender, race, immunosuppression, low income,
and comorbidity was 0.48 (95% CI 0.39–0.56) (Table 3).
Incorporating age at the start of the study as a continuous variable
did not change study findings: adjusted VE, 0.48 (95% CI 0.40–
0.56). The median time to vaccine failure was 168 d. In
immunocompromised vaccinees, there were 24 events in 1,981
person-years of follow-up, giving an adjusted VE of 0.37 (95% CI
0.06–0.58). Adjusting for state quintiles of either proportions
receiving herpes zoster vaccination or proportions with incident
herpes zoster did not modify study findings (adjusted VE 0.48
[95% CI 0.30–0.56] and 0.48 [95% CI 0.30–0.56, respectively]).
Proportions vaccinated per state varied from 0.05% to 11.02%
(Figure 2) and proportions of individuals developing incident
herpes zoster during follow-up per state varied from 0% to 7%. At
90 d or greater following zoster, the adjusted VE was 0.59 (95%
CI 0.21–0.79) for PHN in vaccinees compared to those not
vaccinated, after adjusting for age, gender, race, and other
comorbidities (numbers suppressed to remain compliant with
CMS’s small-sized cell privacy policy). At 30 d or longer following
zoster, 16 vaccinees developed PHN during 71,457 person-years of
follow-up compared to 1,665 events during 2,563,404 person-
years of follow-up in those not vaccinated, giving an adjusted VE
of 0.62 (95% CI 0.37–0.77) for PHN, after adjusting for age,
gender, race, immunosuppression status, and other comorbidities
(Table 4). Results of the logistic regression analysis amongst those
with zoster showed materially similar estimates of protection
against PHN, albeit with wider confidence intervals (adjusted VE
0.64 [95% CI 0.11–0.85]). Lower VE against incident herpes
zoster and PHN was seen when using the general rather than the
specific disease definition.
Discussion
This is the first population-based study, to the best of our
knowledge, to demonstrate the effectiveness of herpes zoster
vaccination against PHN in a routine population setting. Study
findings are consistent with efficacy data from the Shingles
Prevention Study (SPS) randomised controlled trial (RCT) [3].
This work complements the findings of previous observational
studies that have shown effectiveness of herpes zoster vaccination
in immunocompetent insured individuals in southern California
and in older individuals with selected immune-mediated diseases,
as this study is the first study to the best of our knowledge to
determine effectiveness against incident herpes zoster in a
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Figure 1. Flow chart of analysis cohort.
doi:10.1371/journal.pmed.1001420.g001
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population-based cohort of older individuals across the US, not
restricted by geographic region, immune status, or insurance status
[5,6].
Low uptake of herpes zoster vaccination (4%) was seen overall
with variations in uptake by age, race, and low income levels.
Overall VE of 48% was demonstrated against incident herpes
zoster, 62% against PHN after 30 d and 59% against PHN after
90 d. In immunosuppressed individuals, VE against incident
herpes zoster was 37%.
In the SPS RCT, Oxman et al. demonstrated herpes zoster
vaccine efficacy against incident herpes zoster (51%) and PHN
(67%) in 38,546 immunocompetent individuals (19,270 of whom
were vaccinated) aged 60 y or greater with no history of herpes
zoster [3]. Subsequent to this study, Schmader et al. performed an
RCT in 22,439 immunocompetent individuals aged 50–59 y in
North America and Europe, demonstrating vaccine efficacy of
69.8% for incident herpes zoster; efficacy against PHN was not
determined [4]. Our findings are closer to those of the SPS study
with similar estimates and confidence intervals for VE against
incident zoster, which likely relates to the older age of participants
in our study population. Our findings for VE against PHN were
similar to those observed in the SPS trial [3]. RCTs typically have
excellent internal validity, but post-licensure observational studies
are necessary to inform generalisability of research findings.
Our study also confirms the results of the study by Tseng et al.,
which demonstrated the effectiveness of the herpes zoster vaccine
against herpes zoster incidence in 75,761 immunocompetent
vaccinees aged 60 y or greater matched (1:3) to unvaccinated
members; all study participants were fully insured individuals in
Kaiser Permanente Southern California [5]. The authors reported
VE of 55% against incident herpes zoster, which is very similar to
our estimates, despite differences in the study population. Zhang et
al. assessed herpes zoster VE in 463,541 Medicare beneficiaries
aged 60 y or greater with a restricted range of immune-mediated
diseases and 18,683 vaccinees and found an adjusted hazard ratio
of 0.61 (95% CI 0.52–0.71) overall [6]. The lower VE in this
population likely reflects their underlying immunosuppression.
The authors did not observe an increase in risk of herpes zoster
following vaccination in those with immune-mediated disease, nor
did they detect any cases of herpes zoster in individuals vaccinated
while on biologic therapy.
Medicare is an administrative data source so some misclassifi-
cation of exposures and outcomes is possible. However, this
misclassification is likely to be random leading to the possibility of
bias towards the null. Despite taking steps to guard against
misclassification of the PHN by using the method proposed by
Klompas et al. [14] for administrative data sources, the incidence
of PHN in this study is lower than in the SPS [3]—1.38 per 1,000
person-years in the placebo group compared to 0.65 per 1,000 in
the unvaccinated in our study—which might suggest some
misclassification. In a recent study combining administrative data
with medical record review, 3.9% of those with zoster developed
PHN, which is lower than the 6.7% of people observed in this
study [16]. There is a possibility that we underestimated herpes
zoster vaccine uptake if individuals paid for their own vaccination;
however, given that all of these individuals have part D Medicare
(drug benefit) coverage, individual payment is unlikely because of
the cost of the vaccine (US$159 for a single dose, not including
administration costs). As these are observational data, the
exposure—herpes zoster vaccination—was not randomly allocat-
ed. Our study demonstrates that vaccine uptake was not random
and was likely to have been influenced by the demographic
characteristics of beneficiaries. As data on exposures and outcomes
were not collected for research purposes, there are unmeasured
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potential confounders including smoking and obesity, which are
not routinely recorded in an administrative data source, despite
the availability of diagnostic codes. Previous studies have not
suggested that either of these covariates are major risk factors for
the development of incident herpes zoster or PHN and, therefore,
they are unlikely to confound the associations [15]. The study
period was relatively short; the first 12 mo following eligibility was
excluded to enable study of incident rather than prevalent herpes
zoster. This limited duration results in the inability to study long-
term vaccine effects but does not impact the study of VE.
Additionally, while VE was assessed in individuals with immuno-
suppression, assessment of adverse effects or vaccine safety was not
the hypothesis under study. The number of vaccinated immuno-
suppressed individuals in the study was modest resulting in a lack
of precision of the estimate of VE in this group.
Our study is a large population-based cohort; the size of the
cohort gives sufficient statistical power to study VE against herpes
zoster and PHN and results are estimated relatively precisely; our
findings would be unlikely if there was no effect in the population.
In addition, Medicare beneficiaries are reasonably representative
of the general US elderly population, with 98% of Americans aged
65 y or greater being enrolled in Medicare in 2009, increasing the
generalisability of our findings [13]. Medicare datasets have high
quality data available on demographic details of beneficiaries and
clinical encounters, including prescription data. A strict definition
for herpes zoster was used and therefore misclassification of
incident herpes zoster is not likely, although it is not possible to
completely exclude misclassification [16,17]. The higher VE when
using the specific definition could reflect some misclassification of
zoster using the general definition. Alternatively, those with zoster
who did not receive antivirals might include a large proportion
with very mild disease; in the SPS, the zoster vaccine was shown to
have higher efficacy against zoster with appreciable acute
morbidity than against any zoster [3]. If those not receiving
antivirals had milder incident zoster, this could lead to over-
estimation of VE while providing reasonable estimates for
significant zoster episodes. In this study VE was determined after
adjusting for a wide range of confounders, including demographic
details, immunosuppression, and immune-mediated diseases;
despite the large size of this dataset, in some instances adjusting
for confounding led to wide confidence intervals, for example
when assessing VE in immunocompromised vaccinees.
Conclusions
Herpes zoster vaccination was associated with a significant
reduction in incident herpes zoster and PHN in routine clinical
use. This study also supports effectiveness of the vaccine against
incident herpes zoster in immunosuppressed individuals, although
the number of immunosuppressed individuals was small, resulting
in lack of precision in the estimate. Given that these individuals are
Figure 2. Percentage vaccinated by state. Alaska and Hawaii not included in this figure for graphical reasons.
doi:10.1371/journal.pmed.1001420.g002
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at greatest risk of both herpes zoster and complications, this may
have important implications for policy. The findings are relevant
beyond US medical practice, being of major importance to the
many countries, including the UK, that are actively considering
introducing the zoster vaccine into routine practice in the near
future.
Despite strong evidence supporting its effectiveness, clinical use
remains disappointingly low with particularly low vaccination rates
in particular patient groups. This study shows that herpes zoster
vaccination is associated with a reduction in PHN in routine
clinical use. As PHN is the major complication of herpes zoster
and is associated with highly significant morbidity and adverse
impacts on quality of life, substantial efforts are needed to increase
vaccine use in routine care of elderly individuals.
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Editors’ Summary
Background. Chickenpox is an extremely common child-
hood infectious disease that is caused by the herpes
varicella-zoster virus. Children usually recover quickly from
chickenpox, but dormant varicella-zoster virus persists
throughout life inside the nervous system. The dormant
virus causes no symptoms but if it becomes reactivated, it
causes shingles (zoster), a painful skin rash. Anyone who has
had chickenpox can develop shingles but shingles is most
common and most severe in 60–80-year-old people. Indeed,
about half of people who live to 85 will have an episode of
shingles. Early signs of shingles include burning or shooting
pain and tingling or itching. Blister-like sores, which last from
1–14 days, then develop in a region of one side of the body
or on one side of the face. The pain of shingles can be
debilitating and can continue after the rash disappears—
‘‘post-herpetic neuralgia,’’ which can last for months to years,
greatly reduces the quality of life. There is no cure for
shingles but early treatment with antivirals may help to
prevent lingering pain by inhibiting viral replication.
Why Was This Study Done? Shingles vaccination can
prevent shingles or lessen its effects. In clinical trials,
vaccination reduced the incidence of shingles (the propor-
tion of a population who develop shingles in a year) and the
incidence of post-herpetic neuralgia, and vaccination against
shingles is now recommended in the US for everyone over
the age of 60 except individuals with a weakened immune
system (for example, people with HIV/AIDS). However, these
clinical trials determined the vaccine’s efficacy in selected
populations under controlled conditions. How effective is
the vaccine in unselected populations in routine clinical use?
In this cohort study, the researchers assess zoster (shingles)
vaccine effectiveness against incident shingles and post-
herpetic neuralgia in an unselected population of older
individuals in the US. A cohort study follows a group of
individuals who differ with respect to specific factors (in this
study, vaccination against shingles) to determine how these
factors affect the rates of specific outcomes (shingles and
post-herpetic neuralgia).
What Did the Researchers Do and Find? The researchers
undertook their cohort study in 766,330 randomly chosen
Medicare beneficiaries aged 65 years or more. Medicare is a
US government health insurance scheme that mainly helps
to pay the health care costs of people aged 65 or older. The
researchers used Medicare administrative data to identify
which cohort members received zoster vaccination between
January 2007 and December 2009 and which developed
incident shingles (defined as a first diagnosis of shingles
combined with the use of antivirals) or post-herpetic
neuralgia (defined as a code for post-herpetic neuralgia,
non-specific neuralgia, or a second diagnostic code for
shingles 90 days after the first diagnosis combined with a
prescription for pain relief, an anticonvulsant, or an antide-
pressant). Vaccine uptake was low in this unselected study
population—only 3.9% of the participants were vaccinated.
The vaccination rate was particularly low among black
people (0.6% of person-time) and among people with a low
income (0.3%). About 13,000 participants developed incident
shingles. The shingles incidence rate was 10.0 per 1,000
person-years among unvaccinated participants and 5.4 per
1,000 person-years among vaccinated participants. Vaccine
effectiveness against incident shingles was 48%. That is,
vaccination reduced the incidence of shingles by 48% (in
other words, approximately half as many vaccinated individ-
uals developed shingles as those who were not vaccinated).
Vaccine effectiveness against incident shingles among
immunosuppressed individuals was lower (37%). Finally,
vaccine effectiveness against post-herpetic neuralgia was
59%.
What Do These Findings Mean? These findings show
that shingles vaccine uptake is low among elderly people in
the US and varies between different patient groups. They
show that shingles vaccination is effective against incident
shingles in a general population of older individuals,
including those who are immunosuppressed, and suggest
that shingles vaccination is effective against post-herpetic
neuralgia. However, because these findings rely on admin-
istrative data, their accuracy may be affected by misclassi-
fication of vaccination and of outcomes. Moreover, because
shingles vaccination was not randomized, the vaccinated
individuals might have shared other characteristics that were
actually responsible for their lower incidence of shingles
and/or post-herpetic neuralgia compared to unvaccinated
individuals. Despite these limitations, these findings provide
useful information for policy makers in countries that are
currently considering the introduction of shingles vaccina-
tion into routine practice. Moreover, they highlight the need
to increase shingles vaccination among elderly individuals in
the US, the section of the population at the highest risk of
post-herpetic neuralgia.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001420.
N The US Centers for Disease Control and Prevention have
detailed information about all aspects of shingles (zoster),
including information on vaccination for the public and for
health care professionals, and a personal story about
shingles
N The NIH Senior Health website includes information on
shingles and a video describing a personal experience of
shingles
N The UK National Health Service Choices also provides
information about all aspects of shingles and a personal
story
N MedlinePlus provides links to other resources about
shingles (in English and Spanish)
N The British Association of Dermatologists website has an
information leaflet on shingles
N The New Zealand Dermatological Society website has a
leaflet on shingles
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